Lars Engstrom

Lars Engstrom is a seasoned scientist with extensive experience in translational biology and pharmacology. Currently serving as Senior Principal Scientist at Iambic Therapeutics since July 2025, Lars previously held the role of Senior Principal Scientist at Mirati Therapeutics from July 2016 to December 2024, leading the MTA-cooperative PRMT5 pharmacology team and advancing programs from target validation to IND submission. Lars's prior experience includes a decade at Pfizer, where responsibilities included developing in vitro assays for oncology compounds and optimizing assays for pharmacodynamic relationships. Lars began a research career at the University of Michigan's Comprehensive Cancer Center, focusing on DNA binding and protein interactions. Educational background includes a Bachelor of Science degree from the University of Michigan, preceded by study at Albion College.